Not only do pharmacy benefit managers profit thousands of percent using spread pricing, but the spreads are growing; support for Medicare for all is growing among Democrats in Congress, but it's still unclear how such a drastic chage would impact the complex American healthcare system; while precision medicine has great potential, it still has far more failures than successes, but that isn't usually discussed.
Pharmacy benefit managers (PBMs) make part of their profit on spread pricing, in which companies mark up the difference between the amount they reimburse for a drug and what they charge clients. A new investigation from Bloomberg showed that not only do PBMs profit thousands of percent using this tactic, but the spreads are growing. Spread pricing is most common with generic drugs that cost pennies compared with brand-name drugs. While use of generic drugs has been promoted to control rising drug costs, spread pricing may be undercutting those expected savings, according to critics of the tactic.
Senator Bernie Sanders, I-Vermont, does not stand alone—more Democrats are embracing his idea of Medicare for all. While the idea is gaining momentum among Democrats in Congress, as well as the general public, it’s unclear how such a drastic change would impact the complex American healthcare system. Politico pulled together a guide to Medicare for all that answered questions as simple as “what does it actually mean?” as well as more complex ones, such as “what happens to doctors?”
The future of healthcare is a system in which doctors can match patients with the best drug for them and their disease by targeting genetic mutations. While future potential is far from the reality of today, that isn’t always explained. An opinion piece in The New York Times explained that the number of people who can currently be helped with precision medicine is still very small, and successes remain rare. One study found that precision medicine failed to help 93% of 1000 patients treated, while 2 others reported failure to shrink tumors 92% and 95% of the time. Unfortunately, the failures are not always discussed or covered, which can paint a misleading picture of precision medicine.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More